Commercial

Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.

Barcelona-based accelerator S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity. This month, the accelerator will add a fourth cohort of 10 more start-ups, five of which are in the medtech space.

Three $1bn+ alliances were penned in February, and one exceeded $2bn.

Deal Snapshot: The antibody-drug conjugate field continues one of the hottest dealmaking spaces and Roche continues to invest heavily. Its latest pact could be transformative for the UK firm which already has a decent number of big pharma partners.

ModMed unveiled its AI-powered ambient listening and clinical documentation software for orthopedic clinics at AAOS, ahead of its planned late-summer release. The health care software provider aims to create “the AI-powered practice” for specialty clinics to reduce clinicians' administrative burden and streamline clinical workflows.

The Swiss giant has inked a deal potentially worth $5.30bn with Zealand to access the Danish biotech's long-acting amylin analog petrelintide.

Chairman Antoine Papiernik spoke to Scrip about the therapeutic areas that where the VC major is looking at to invest its considerable cash pile.

The late-stage cupboard is looking bare but the German firm has its eyes on products with peak sales potential of over €500m.

Pharma revenues are going to fall this year as a result of deeper generic competition for the German group’s top-selling drug, Xarelto, but it should return to growth from 2027 onwards.

China's medical equipment industry is growing rapidly, driven by limited domestic presence in high-cost segments and increasing adoption of local products in areas like monitoring equipment, defibrillators, and ventilators. International giants dominate the high-end market, but domestic companies such as Neusoft Medical Systems and Mindray Medical are making significant strides.